Thyroid Cancer and Hormones: What's the Connection?
"Exploring the role of estrogen and progesterone receptors in papillary thyroid carcinoma and what it means for women's health."
Thyroid cancer stands as the most prevalent malignancy of the endocrine system, with papillary thyroid carcinoma (PTC) leading the charge. While factors like radiation exposure are known contributors, the striking female predominance in thyroid cancer cases suggests hormones might play a more significant role than previously understood.
Oestrogens, key hormones in female physiology, have been shown to influence the development of papillary carcinoma by fueling cell proliferation and invasion, underscoring a potentially critical link between hormonal activity and thyroid cancer progression.
This article delves into the role of estrogen receptor alpha (ER-α) and progesterone receptor (PR) expression in PTC. We'll explore how these hormone receptors might impact the clinicopathological characteristics of thyroid cancer. Ultimately, understanding this relationship can open doors to more targeted and effective therapies.
The Significance of Estrogen and Progesterone Receptors in Thyroid Cancer
A study examining 62 primary and six metastatic papillary thyroid carcinoma cases revealed intriguing insights into ER-α and PR expression. The findings indicated that 19% of primary PTC cases showed positive nuclear expression for ER-α, while 38.7% exhibited PR expression. Notably, metastatic cases displayed a higher ER expression (66.7%) but were negative for PR.
- ER-α and Metastasis: ER-α expression shows a greater positivity in metastatic sites versus primary PTC, signifying malignant potential.
- ER-α and Thyroiditis: Primary PTC cases associated with thyroiditis exhibited a significant association with ER-α.
- PR and Age: Progesterone receptor expression associates significantly with older age in primary PTC cases.
- ER and PR Correlation: ER and PR demonstrate significant co-expression, enhancing the opportunity for hormonal therapies.
Limits in the Evidence
The meta-epidemiological analysis of prospective cohort studies reports heterogeneity of I² = 64.3% and says it used a random-effects model for that reason. This indicates that the cohort findings varied rather than reflecting one uniform estimate. That variability is important to keep in mind when interpreting the pooled association.
Future Directions and Hope for Thyroid Cancer Patients
The study's results highlight the potential for hormone-targeted therapies in treating thyroid cancer, particularly in metastatic cases. The presence of lymphocytes in the stroma may promote ER expression in adjacent PTC, warranting further studies on PTC cases associated with Hashimoto thyroiditis to verify this assumed relationship. While more research is needed, these findings offer a promising step forward in personalizing thyroid cancer treatment and improving patient outcomes.
Balancing Guidance and Treatment Risks
The 2025 American Thyroid Association guideline panel included members from multiple specialties involved in thyroid cancer care, a patient advocate, and an expert in systematic reviews, meta-analyses, and guidelines. A review published May 26, 2025, aims to delineate the risks and benefits of TSH suppression therapy in patients with differentiated thyroid cancer (DTC). Together, these sources highlight multidisciplinary guideline development and consideration of both benefits and risks in treatment decisions.
Challenges in Advanced Disease
The source reports that thyroid cancer generally has very favorable outcomes with standard therapy, with anaplastic thyroid cancer as an exception; persistent, recurrent, or metastatic disease is associated with a worse prognosis. It also reports that, as of August 29, 2025, advanced thyroid cancer management remained challenged by drug resistance and toxicity. The source identifies universal access to molecular testing and targeted therapies as areas needing improvement.
Estrogen and Progression
A 2024 review of complex hormone regulation in thyroid cancer cites a nationwide cohort study conducted in Korea. That study found that estrogen and related hormone receptors only slightly promoted thyroid cancer progression, while the absence of estrogen did not protect against disease onset. These findings describe the cohort’s results and do not establish that estrogen absence prevents or causes thyroid cancer.